Clinical Study

Systemic Inflammation and Lung Function Impairment in Morbidly Obese Subjects with the Metabolic Syndrome

Astrid van Huisstede, 1 Manuel Castro Cabezas, 2 Erwin Birnie, 3,4 Gert-Jan M. van de Geijn, 5 Arjan Rudolphus, 1 Guido Mannaerts, 6 Tjin L. Njo, 5 Pieter S. Hiemstra, 7 and Gert-Jan Braunstahl 1

1 Department of Pulmonology, Sint Franciscus Gasthuis, Kleiweg 500, 3045 PM Rotterdam, The Netherlands
2 Department of Internal Medicine, Sint Franciscus Gasthuis, 3045 PM Rotterdam, The Netherlands
3 Department of Statistics, Sint Franciscus Gasthuis, 3045 PM Rotterdam, The Netherlands
4 Institute of Health Policy and Management, Erasmus University Rotterdam, 3000 DR Rotterdam, The Netherlands
5 Department of Clinical Chemistry, Sint Franciscus Gasthuis, 3045 PM Rotterdam, The Netherlands
6 Department of Surgery, Sint Franciscus Gasthuis, 3045 PM Rotterdam, The Netherlands
7 Department of Pulmonology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands

Correspondence should be addressed to Astrid van Huisstede; a.vanhuisstede@sfg.nl

Received 7 October 2012; Revised 6 January 2013; Accepted 26 January 2013

Academic Editor: David Allison

Copyright © 2013 Astrid van Huisstede et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Obesity and asthma are associated. There is a relationship between lung function impairment and the metabolic syndrome. Whether this relationship also exists in the morbidly obese patients is still unknown.

Hypothesis. Low-grade systemic inflammation associated with the metabolic syndrome causes inflammation in the lungs and, hence, lung function impairment.

Methods. This is cross-sectional study of morbidly obese patients undergoing preoperative screening for bariatric surgery. Metabolic syndrome was assessed according to the revised NCEP-ATPIII criteria.

Results. A total of 452 patients were included. Patients with the metabolic syndrome (n = 293) had significantly higher blood monocyte (mean 5.3 versus 4.9, P = 0.044) and eosinophil percentages (median 1.0 versus 0.8, P = 0.002), while the total leukocyte count did not differ between the groups. The FEV1/FVC ratio was significantly lower in patients with the metabolic syndrome (76.7% versus 78.2%, P = 0.032). Blood eosinophils were associated with FEV1/FVC ratio (adj. B = −0.113, P = 0.018).

Conclusion. Although the difference in FEV1/FVC ratio between the groups is relatively small, in this cross-sectional study, and its clinical relevance may be limited, these data indicate that the presence of the metabolic syndrome may influence lung function impairment, through the induction of relative eosinophilia.

1. Introduction

Obesity is an increasing worldwide problem that has taken on epidemic proportions [1]. Cross-sectional studies have shown a positive association between obesity and asthma [2]. Weight loss in obese asthma patients improved morbidity and lung function [3]; however, the mechanisms underlying the relationship between asthma and obesity are unclear. It is suggested that low-grade systemic inflammation associated with obesity plays a role.

The metabolic syndrome is a common metabolic disorder that may result from the increasing prevalence of obesity. Metabolic syndrome is a cluster of cardiometabolic risk factors characterized by abdominal obesity, insulin resistance, and chronic systemic inflammation [4]. Positive associations with lung function impairment have been reported for components of the metabolic syndrome, such as hypertension [5], type diabetes mellitus [6, 7], low-density lipoprotein cholesterol [8], and overall obesity [9]. In recent large cohort studies, it has been shown that there is also a relationship between lung function impairment and the metabolic syndrome [10–12]. However, all the aforementioned studies included overweight as well as normal weight subjects and were therefore not specifically targeted to examine these
issues in the morbidly obese. Data on the association between lung function impairment and the metabolic syndrome in the morbidly obese are limited.

The mechanisms underlying the relationship between impaired lung function and the metabolic syndrome are unclear. The chronic low-grade systemic inflammation that is associated with obesity might explain this relationship. Our hypothesis is that this low-grade systemic inflammation causes inflammation in the lungs and, hence, lung function impairment.

We therefore performed a study to investigate (1) the association between lung function and the metabolic syndrome in morbidly obese subjects and (2) to determine the effect of systemic inflammation on the relationship between lung function impairment and the metabolic syndrome.

2. Methods

2.1. Study Population. The subjects included in this study were consecutive patients who underwent preoperative screening for bariatric surgery in the Sint Franciscus Gasthuis in Rotterdam, The Netherlands, between October 2009 and May 2011. Eligibility criteria for bariatric surgery were age between 18 and 60 years and body mass index (BMI) either ≥40 kg/m² or ≥35 kg/m² combined with the presence of comorbidity, for example, diabetes mellitus, hypertension, or proven obstructive sleep apnea syndrome (OSAS). Subjects underwent baseline physical examinations that included routine assessment of anthropometry, blood pressure, pulmonary function, and blood samples.

Height and weight were measured wearing light clothes and no shoes. Body mass index was calculated as weight (in kg) divided by height (in m) squared. Abdominal circumference was measured directly to the body surface midway between the lower rib margin and the iliac crest.

The Epworth Sleepiness Scale questionnaire [13] was used to assess OSAS and the GERD questionnaire [14] for gastroesophageal reflux disease (GERD).

All subjects gave informed consent, and the local ethics committee (Toetsingscommissie Wetenschappelijk Onderzoek Rotterdam e.o, Trial no. NL25637101.08) approved the study protocol (The Netherlands Trial Register no. NTR3204).

2.2. Definition of the Metabolic Syndrome. Metabolic syndrome was diagnosed according to the National Cholesterol Education Program's Adult Treatment Panel III report (NCEP ATP-III) criteria when ≥3 of the following 5 risk factors were present: abdominal obesity, an elevated level of serum triglycerides, low serum level of high-density lipoprotein cholesterol (HDL-C), elevated blood pressure, and high serum glucose level or treatment for any of these disorders [4].

2.3. Pulmonary Function Tests. Spirometry was performed with Vmax spirometer (Vmax SensorMedics Viasys, type Encore 20/22/229/62 Encore, Cardinal Health, USA) before and after 400 µg of inhaled salbutamol, with subjects in a sitting position and nose clips in place according to the American Thoracic Society/European Respiratory Society statement [15]. All values obtained were related to height, age, and gender and expressed as percentage of their predicted value (reference ERS 1993). The pulmonary function results are prebronchodilator values unless specifically noted. Exhaled nitric oxide (FeNO) was measured with NIOX MINO (Aerocrine, Sweden) and expressed in parts per billion (ppb).

2.4. Clinical Chemistry. Blood was taken by venipuncture during routine preoperative screening. Laboratory measurements were performed according to standard procedures by our Department of Clinical Chemistry. Plasma-cholesterol, HDL-cholesterol, glucose, triglycerides, and CRP were measured using LX 20 and DxC analyzers (Beckman Coulter, Miami, FL, USA). LDL-cholesterol was calculated using the Friedewald formula. Total IgE and specific plasma IgE were determined with a solid-phase two-step chemiluminescent immunoassay on the Immulite 2000 (Siemens, Los Angeles, CA). A positive inhalation screen was defined as at least one increased amount of specific IgE against one of the following allergens: Aspergillus fumigatus, house-dust mite, cat, dog, grass, birch, or herbs. Blood cell counts and 5-part leukocyte differentiation were determined automatically using LH750 analyzers (Beckman Coulter). HbA1C was determined using a Tosoh G8 HLC-723 analyzer (Tosoh Bioscience, Tokyo, Japan). Insulin was measured using radio immunoassay (RIA) DSL1600 (Diagnostic Systems Laboratories, Webster, TX, USA). Vitamin D was determined by RIA or chemiluminescence (LIA) on Liaison analyzers (DiaSorin, Stillwater, MN, USA).

2.5. Statistical Analyses. Unadjusted between-group comparisons were performed using Student's t test or the Chi-square test, where appropriate, and Mann-Whitney U test for nonparametric comparisons (eosinophils). CRP, IgE, insulin, lipoprotein-a, and vitamin B6 were not normally distributed (standard error of kurtosis and skewness below −3 or above 3) and were therefore log transformed. Univariate linear regression was used to evaluate associations between continuous variables. Backward linear regression analysis was used to investigate which component of the metabolic syndrome is related to the FEV₁/FVC ratio. Variables associated with FEV₁/FVC ratio in univariate analysis at a P-value of <0.1 were examined in the multiple linear regression analysis. Since the FEV₁/FVC ratio as percentage predicted is already corrected for height, age, and gender, we did not add these variables to the model. As eosinophils and abdominal circumference were correlated, we selected only eosinophils to prevent collinearity. We omitted OSAS because of the large proportion of missing data. All analyses were performed using SPSS 18.0 software (SPSS Inc., Chicago, IL, USA). Results were evaluated at 95% confidence interval at a two-sided P < 0.05.
Table 1: General characteristics of the population included in the study.

|                                      | No metabolic syndrome (𝑛 = 159) | Metabolic syndrome (𝑛 = 293) | 𝑃 value |
|--------------------------------------|---------------------------------|-------------------------------|---------|
| Age (years)                          | 37 ± 11                         | 43 ± 10                       | <0.001  |
| BMI (kg/m²)                          | 45.4 ± 6.7                     | 46.0 ± 6.5                   | 0.395   |
| Gender (% female)                    | 87.4%                           | 73.7%                         | 0.001²  |
| Ethnicity (% Caucasian)              | 80.5%                           | 85.0%                         | 0.222   |
| Smoking                              |                                 |                               | 0.152   |
| % never smoked                       | 49%                             | 40%                           |         |
| % stopped smoking                    | 29%                             | 32%                           |         |
| % smokes                             | 22%                             | 28%                           |         |
| Pack years¹                          | 6.0 ± 11.2                      | 9.9 ± 14.8                    | 0.003   |
| Abdominal circumference (cm)         | 126.8 ± 14                      | 134.3 ± 16                   | <0.001  |
| Systolic blood pressure (mm Hg)      | 136.4 ± 17.9                    | 145.98 ± 16.6                | <0.001  |
| Diastolic blood pressure (mm Hg)     | 83.6 ± 11.8                     | 87.83 ± 10.1                 | <0.001  |
| Comorbidities                        |                                 |                               |         |
| Diabetes mellitus                    | 3.8%                            | 30.3%                         | <0.001  |
| Hypertension                         | 18.9%                           | 42.8%                         | <0.001  |
| Hypercholesterolemia                 | 1.9%                            | 21.7%                         | <0.001  |
| Self-reported asthma                 | 19.6%                           | 21.0%                         | 0.723   |
| Use of inhaled corticosteroids       | 3.8%                            | 5.5%                          | 0.413   |

¹Data presented as mean ± standard deviation, 𝑃 value for Student’s 𝑡 test.
²Data presented as percentage, 𝑃 value for Chi-square test.
³Data were log transformed for statistical analysis.

3. Results

3.1. Subjects. A total of 452 subjects were included in the study (97 males and 355 females). Also 293 subjects (64.8%) fulfilled the criteria for metabolic syndrome. Table 1 shows the general characteristics of the study population. Patients with the metabolic syndrome were significantly older (mean 43 years), were less often female (73.7%), and had a larger abdominal circumference in centimeters (mean 134.3 cm) compared to patients without the metabolic syndrome (mean 37 years, 87.4%, and mean 126.8 cm, resp.).

3.2. Metabolic Syndrome and Blood Parameters. Patients with the metabolic syndrome did not have a higher total leukocyte count or neutrophil percentage in the peripheral blood (𝑃 = 0.253), but they did have a significantly higher percentage of eosinophils (𝑃 = 0.002) and monocytes (𝑃 = 0.044) compared to patients without the metabolic syndrome (Table 2). Other parameters of systemic inflammation such as CRP, Complement C3, and Complement C4 did not show significant differences between the two groups (Table 2). There was no correlation between BMI and eosinophils. We did find a low, but significant, correlation between eosinophils and abdominal circumference (Spearman correlation coefficient 0.270, 𝑃 < 0.001) and CRP and abdominal circumference (Spearman correlation coefficient 0.146, 𝑃 = 0.010).

3.3. Metabolic Syndrome and Pulmonary Function Tests. The subjects with the metabolic syndrome showed a significantly lower FEV₁/FVC ratio—a measure for bronchial obstruction—compared to the group without the metabolic syndrome (76.7% and 78.2%, resp., 𝑃 = 0.032), while no difference was observed regarding FEV₁ or FVC (Table 3). Although there was no significant difference in FEF₂₅₋₇₅ between subjects with and without the metabolic syndrome, the FEF₂₅ was significantly lower in the metabolic syndrome group (𝑃 = 0.036). Log transformed FeNO—a measure for bronchial inflammation—showed no difference between the two groups. There was no correlation between BMI and FeNO and abdominal circumference and FeNO.

3.4. Subgroup Analysis: Self-Reported Asthma. There was no difference in the prevalence of self-reported asthma between subjects with or without the metabolic syndrome (21.0% versus 19.6%, resp., 𝑃 = 0.723). In a subgroup analysis of subjects with self-reported asthma, we found no significant difference in the use of inhaled corticosteroids, body mass index, pack years, FEV₁ (% predicted), FEV₁/FVC (% predicted), FeNO, blood eosinophils, or CRP between subjects with or without the metabolic syndrome (data not shown).

3.5. Subgroup Analysis: Reversibility. In a subgroup analysis of subjects with and without reversibility (ΔFEV₁ ≥ 12%), we found that only 50% of subjects with reversibility (𝑛 = 30) had self-reported asthma. Although subjects with reversibility did use more often inhaled corticosteroids (13.3% versus 4.4%, 𝑃 = 0.032), there was no significant difference in FeNO, blood eosinophils, or CRP between subjects with and without the metabolic syndrome.

3.6. Variables Related with FEV₁/FVC Ratio. Since the FEV₁/FVC ratio was the only variable of spirometric function
Table 2: Comparison of blood parameters between subjects with and without metabolic syndrome.

| Parameter                        | No metabolic syndrome (n = 159) | Metabolic syndrome (n = 293) | P value |
|----------------------------------|---------------------------------|-----------------------------|---------|
| Leukocytes (10^9/L)              | 8.6 ± 2.3                       | 8.9 ± 2.1                   | 0.253³  |
| Neutrophils (%)                  | 70.1 ± 8.6                      | 68.9 ± 9.1                  | 0.186   |
| Lymphocytes (%)                  | 23.7 ± 7.1                      | 23.8 ± 7.0                  | 0.844   |
| Monocytes (%)                    | 4.9 ± 1.8                       | 5.3 ± 1.9                   | 0.044   |
| Eosinophils (%)                  | 0.82 (0.05–1.07)                | 1.00 (0.45–1.85)            | 0.002²  |
| CRP (mg/L)³                      | 9.6 ± 7.4                       | 9.5 ± 8.0                   | 0.865   |
| Cholesterol (mmol/L)             | 5.2 ± 1.0                       | 5.1 ± 1.1                   | 0.198   |
| HDL-cholesterol (mmol/L)         | 1.3 ± 0.3                       | 1.1 ± 0.2                   | <0.001  |
| LDL-cholesterol (mmol/L)         | 3.5 ± 0.9                       | 3.3 ± 1.1                   | 0.108   |
| Triglyceride (mmol/L)            | 1.0 ± 0.4                       | 1.6 ± 1.0                   | <0.001  |
| Glucose (mmol/L)                 | 6.3 ± 1.3                       | 8.2 ± 3.9                   | <0.001  |
| HbA1C (%)                        | 5.52 ± 0.4                      | 6.4 ± 1.5                   | <0.001  |
| Insulin (mE/L)³                  | 56.2 ± 58.1                     | 75.0 ± 79.4                 | <0.001  |
| Vitamin D (nmol/L)               | 39.5 ± 22.9                     | 38.5 ± 17.7                 | 0.661   |
| IgE (kU/L)³                      | 213.5 ± 479.9                   | 1978 ±391.3                 | 0.141   |
| Positive inhalation screen       | 46.2%                           | 44.0%                       | 0.694   |

¹Data presented as mean ± standard deviation, P value for Student’s t-test.
²Data presented as median (1st–3rd quartiles), P value for Mann-Whitney U test.
³Data were log transformed for statistical analysis.

Table 3: Pulmonary function test of subjects with and without metabolic syndrome.

| Parameter                        | No metabolic syndrome (n = 159) | Metabolic syndrome (n = 293) | P value |
|----------------------------------|---------------------------------|-----------------------------|---------|
| FEV₁ (% predicted)              | 93.0 ± 13.9                     | 91.2 ± 14.5                 | 0.206⁶  |
| FVC (% predicted)               | 100.6 ± 14.0                    | 98.5 ± 14.7                 | 0.206   |
| FEV₁/FVC                        | 78.2 ± 6.9                      | 76.7 ± 6.4                  | 0.032   |
| FEF₂₅–₇₅ (% predicted)           | 77.4 ± 24.0                     | 73.9 ± 23.3                 | 0.152   |
| Reversibility FEV₁ > 12%        | 6%                              | 7%                          | 0.523²  |
| FeNO (ppb)³                     | 19.3 ± 22.4                     | 17.6 ± 12.6                 | 0.541   |

¹Data were log transformed before comparison.
²Data presented as percentage, P value for Chi-square analysis.
³Data presented as mean ± standard deviation, P values for Student t-test.
⁶FEV₁: forced expired volume in 1 second; FVC: forced vital capacity; FEF₂₅–₇₅: forced expiratory flow 25–75%; TLC: total lung capacity; FeNO: fractional expiratory nitric oxide.

tests which was different between subjects with and without the metabolic syndrome and our hypothesis was that the metabolic syndrome causes a lower FEV₁/FVC ratio—not the other way around—we investigated which variables were related to the FEV₁/FVC ratio. There was an association between the peripheral blood eosinophils percentage and the FEV₁/FVC ratio (univariate linear regression coefficient = −0.806, P = 0.006). Abdominal circumference and OSAS (Epworth Sleepiness Scale (ESS)) were significantly related to the FEV₁/FVC ratio (univariate linear regression analysis), whereas BMI, GERD, CRP and monocytes were not significantly related to the FEV₁/FVC ratio (Table 4). Missing values of ESS were not correlated to other variables.

Since the metabolic syndrome was associated with the FEV₁/FVC ratio, we investigated which of the components of the metabolic syndrome contributed to this relationship. Only hypertension was significantly related to FEV₁/FVC ratio (regression coefficient = −1.612, P = 0.038 in backward linear regression analysis) (Table 5).

3.7 Multiple Regression Analysis. After correction for the use of inhaled corticosteroids and the number of pack years, we found an association between blood eosinophils and the FEV₁/FVC ratio (adj. B = −0.113, P = 0.018) (Table 6).

4. Discussion

This study shows that obese patients with the metabolic syndrome have a higher proportion of blood monocytes and eosinophils and a lower FEV₁/FVC ratio, indicating airway obstruction, than obese patients without the metabolic syndrome. Blood eosinophils (%) in morbidly obese subjects were related to FEV₁/FVC, whereas monocytes were not. After adjustment for multiple variables, the relationship
Table 4: Univariate linear regression analysis of FEV$_1$/FVC.

|                          | Regression coefficient | Standard error | $P$ value
group \( n = 148 \) | 1
|--------------------------|------------------------|----------------|-----------------
| Monocytes (%)            | -0.079                 | 0.162          | 0.626          |
| Eosinophils (%)          | -0.806                 | 0.290          | 0.006          |
| CRP (mg/mL)              | 0.075                  | 0.045          | 0.098          |
| Abdominal circumference (cm) | -0.058               | 0.021          | 0.006          |
| Body mass index (kg/m$^2$) | 0.041                 | 0.047          | 0.387          |
| OSAS (Epworth Sleepiness Scale)$^1$ | 0.311                 | 0.141          | 0.029          |
| GERD (GERD questionnaire) | 0.068                 | 0.157          | 0.667          |

$^1$Missing values $n = 148$.

$^2$Data presented as linear regression coefficient, $P$ value for simple linear regression analysis. OSAS: obstructive sleep apnea syndrome; GERD: gastro esophageal reflux disease.

Table 5: Univariate regression analysis of relation of components of metabolic syndrome and FEV$_1$/FVC ratio.

|                          | Regression coefficient | Standard error | $P$ value
group \( n = 408 \) | 1
|--------------------------|------------------------|----------------|-----------------
| Abdominal circumference | NA                     |                |                |
| Hypertriglyceremia       | -1.119                 | 0.739          | 0.130          |
| Low serum HDL-cholesterol | 0.712                | 0.686          | 0.300          |
| Hypertension             | -1.612                 | 0.774          | 0.038          |
| High serum glucose       | -0.010                 | 0.753          | 0.989          |

$^1$Data presented as linear regression coefficient, $P$ value for linear regression analysis. Abdominal circumference is not applicable, because all patients fulfill the criteria for abdominal circumference according to the NCEP-ATP III criteria for metabolic syndrome.

Table 6: Multiple regression analysis FEV$_1$/FVC ratio.

|                          | Regression coefficient | 95% CI         | $P$ value
group \( n = 408 \) (Adj $R^2 = 0.074$) | 1
|--------------------------|------------------------|----------------|-----------------
| Eosinophils (%)          | -0.113                 | -1.247 to -0.118 | 0.018          |
| Use of inhalation corticosteroids | -0.025             | -3.635 to -2.122 | 0.606          |
| Pack years               | -0.259                 | -1.062 to -0.076 | <0.001         

Variables associated with FEV$_1$/FVC ratio in univariate analysis at a $P$ value of $<0.1$ were examined in the multiple linear regression analysis. Since the FEV$_1$/FVC ratio as percentage predicted is already corrected for height, age, and gender, we did not add this variable to the model. As eosinophils and abdominal circumference are correlated, we selected only one variable to prevent colinearity. We omitted OSAS because of the large proportion of missing data.

The prevalence of self-reported asthma was similar in the two groups. We did not perform methacholine-provocation tests; so, a definitive diagnosis of asthma was often not possible. Since misdiagnosis of asthma is a relevant issue, also in the obese [18], we felt more comfortable using objective parameters instead of a presumed diagnosis.

Since the metabolic syndrome was associated with the FEV$_1$/FVC ratio in univariate analysis, we investigated which of the components of the metabolic syndrome contributed to this relationship. Hypertension was the only component that was significantly associated with a reduced FEV$_1$/FVC ratio after multiple backward regression analysis. Hypertension may have the strongest association with systemic inflammation, as proposed by Irace et al. [19]. We could also confirm the results of Leone et al. [10] showing that there have the metabolic syndrome, we found a 65% prevalence of the metabolic syndrome in our group, which corresponds with 60% of the morbidly obese in the NHANES III cohort [16].

Various studies have shown that obesity causes a modest reduction in total lung capacity (TLC) and a larger reduction in functional residual capacity (FRC) [17]. However, we were unable to perform a TLC measurement in all subjects to rule out a restrictive pattern. The FEV$_1$/FVC ratio is usually well preserved in obese subjects, or even increased. This could explain the high mean FEV$_1$/FVC ratio in our subjects, and therefore we have used the FEV$_1$/FVC ratio as a continuous variable and did not use a cutoff value of 70% predicted. Furthermore, in contrast to the FEV$_1$/FVC, the FEV$_1$ is influenced by BMI; hence, our focus is on the FEV$_1$/FVC ratio.

To our knowledge, this is the first study concerning lung function and the metabolic syndrome in a cohort of only morbidly obese subjects. Secondly, comorbid conditions associated with obesity such as OSAS and GERD were taken into account in the current study. Thirdly, adiposity was not only assessed with BMI, but also with abdominal circumference. Although one would expect that all our subjects between FEV$_1$/FVC ratio and eosinophils remained intact. Although the differences are small, it strengthens our hypothesis that the presence of the metabolic syndrome could play a role in lung function impairment, through the induction of systemic inflammation, in particular mediated by blood eosinophils. Whether this also leads to asthma on the long term still remains to be elucidated.
is indeed a relationship between abdominal circumference (in cm) and the FEV₁/FVC ratio. Interestingly, we found a correlation between blood eosinophil percentage and abdominal circumference, where we found no correlation between blood eosinophil percentage and BMI, indicating that it is mainly the place of the fat that matters. This suggests that the increased abdominal circumference of subjects with the metabolic syndrome causes the relative eosinophilia.

Obesity is a state of chronic low-grade systemic inflammation. Leukocyte count is considered a marker of systemic inflammation. Several epidemiological studies have already noted a relationship between some components of metabolic syndrome and leukocytes [20, 21]. Several studies showed an increased eosinophil percentage in obesity [22] or in the metabolic syndrome [20, 21]. C-reactive protein (CRP) is a traditional marker of inflammation and is well correlated with BMI [23]. Even though our study found no difference in CRP between the two groups—we did not use highsensitivity CRP measurements—monocyte and eosinophils percentage in the blood were higher in those with the metabolic syndrome. Our study suggests that increased numbers or circulating eosinophils could be a specific manifestation of the systemic inflammation associated with the metabolic syndrome.

The question remains why there is relative eosinophilia in the obese. Traditionally, eosinophils are related to allergic diseases, asthma, and parasitic infections. The fat tissue is a source of adipokines, which are considered to play a role in the low-grade systemic inflammation in obesity [24]. Leptin—mainly produced by adipose tissue—is a proinflammatory agent. Serum leptin is markedly increased in obese humans, correlating to BMI [25]; it activates eosinophils [26] and increases their survival [27]. Serum leptin levels are elevated in adults of normal weight with impaired lung function [28]. Eotaxin is an eosinophil-specific chemokine that is increased in obesity [29]. Adipocytes produce more eotaxin when stimulated by leptin [30]. Plasma adiponectin—an anti-inflammatory hormone—is reversely correlated to BMI [31]. The leptin/adiponectin ratio is a marker of insulin resistance [32] and the metabolic syndrome [33]. Thus, both leptin and possibly eotaxin could contribute to relative eosinophilia in the obese. Unfortunately, we do not have data on leptin, adiponectin, and eotaxin to further support their role in the observed eosinophilia.

Another question is whether this relative eosinophilia in the peripheral blood also has local effects on the bronchial tissue and causes or enhances the bronchial inflammation as seen in asthma. Asthma-like symptoms are common in patients with the metabolic syndrome, and their pulmonary function is impaired [34, 35]. Although we did find differences in pulmonary function between subjects with and without the metabolic syndrome, there was no difference in prevalence of self-reported asthma between the two groups. This is, however, unreliable in the morbidly obese patients before and after bariatric surgery. de Winter-de Groot et al. showed that a higher BMI was associated with a higher eNO in healthy patients [36]. Several studies have found no—or even an inverse—relationship between the number of sputum eosinophils and BMI [37]. We found no difference in eNO between subjects with and without the metabolic syndrome. Induced sputum or bronchial biopsies could have helped to solve this question but were unfeasible in this study. Since there was no difference in the use of inhaled corticosteroids, this could not have influenced our results of eNO.

Our study includes several limitations. We did not measure TLC values; so, we were not able to firmly assess a restrictive lung function pattern. Also, we did not perform methacholine-provocation tests; so, a definite diagnosis of asthma was often not possible. The FEV₁/FVC ratio, however, is easy to measure and widely used in clinical practice. Although the differences in FEV₁/FVC and eosinophils between subjects with and without the metabolic syndrome were small, the difference was significant despite the fact that our study groups consisted of unselected subjects. There probably is a selection bias since we only included patients who were willing to undergo bariatric surgery. It is widely known that most of the subjects who undergo bariatric surgery are females. This explains the female predominance among our subjects. Furthermore, we did not measure adipocytokines or high-sensitivity CRP. We did not include a non-obese control group as comparison for low-grade inflammation, and we cannot fully exclude that smoking might have contributed to a state of low-grade inflammation. However, we corrected for smoking in the multiple regression analysis. Finally, we realize that a cross-sectional association between metabolic syndrome and lung function cannot establish causality. However, Naveed et al. [12] have recently shown that the metabolic syndrome predicts a steeper FEV₁ decline over time, suggesting that the systemic inflammation produced by metabolic syndrome may impact the progression to abnormal lung function in a longitudinally followed cohort.

In summary, our study shows that there is a small, but statistically significant, difference in eosinophils and FEV₁/FVC between subjects with and without the metabolic syndrome. After correction for other variables, an association between blood eosinophils and FEV₁/FVC remained. Although the differences we have found were relatively small, it might support our hypothesis that the presence of the metabolic syndrome may influence lung function impairment, through the induction of systemic inflammation, in particular, mediated by blood eosinophils. Further research with a firm diagnosis of asthma and assessment of peripheral airway inflammation is necessary. Moreover, in order to establish causality between the metabolic syndrome and lung function impairment, longitudinal studies in morbidly obese patients before and after bariatric surgery are needed.

**Abbreviations**

| Abbreviation | Description |
|--------------|-------------|
| BMI | Body mass index |
| CRP | C-reactive protein |
| ESS | Epworth Sleepiness Scale |
| FEF₂₅–₇₅ | Forced expiratory flow 25%–75% |
FeNO: Fraction of exhaled nitric oxide
FEV₁: Forced expiratory volume in 1 second
FVC: Forced vital capacity
GERD: Gastroesophageal reflux disease
HDL: High-density lipoprotein
NCEP-APT III: National Cholesterol Education Program’s Adult Treatment Panel III report
OSAS: Obstructive sleep apnea syndrome.

Conflict of Interests
The authors declare no conflict of interests.

Acknowledgments
The authors wish to thank Mrs. Sandra Reijnhart for editing the paper. The authors are grateful for the help of all the staff in the Respiratory Laboratory and members of the Bariatric Surgery Team at Sint Franciscus Gasthuis. This research was supported by grants from Foundation for Research and Development, Department of Internal Medicine, Sint Franciscus Gasthuis (Stichting Onderzoek en Ontwikkeling Interne Specialismen Sint Franciscus Gasthuis).

References
[1] WHO, "Obesity and overweight," Fact Sheet no. 311, 2011, http://www.who.int/mediacentre/factsheets/fs311/en/index.html.
[2] E. S. Ford, "The epidemiology of obesity and asthma," The Journal of Allergy and Clinical Immunology, vol. 115, no. 5, pp. 897–909, 2005.
[3] B. Stenius-Aarniala, T. Poussa, J. Kvarnström, E. L. Grönlund, M. Ylikahri, and P. Mustajoki, "Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study," The British Medical Journal, vol. 320, no. 7238, pp. 827–833, 2000.
[4] S. M. Grundy, H. B. Brewer Jr., J. I. Cleeman, S. C. Smith Jr., and C. Lenfant, "Definition of metabolic syndrome: report of the national heart, lung, and blood institute/American heart association conference on scientific issues related to definition," Circulation, vol. 109, no. 3, pp. 433–438, 2004.
[5] J. V. Selby, G. D. Friedman, and C. P. Quesenberry Jr., "Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries," The American Journal of Epidemiology, vol. 131, no. 6, pp. 1017–1027, 1990.
[6] E. S. Ford and D. M. Mannino, "Prospective association between lung function and the incidence of diabetes: findings from the national health and nutrition examination survey epidemiologic follow-up study," Diabetes Care, vol. 27, no. 12, pp. 2966–2970, 2004.
[7] H. C. Yeh, N. M. Punjabi, N. Y. Wang et al., "Cross-sectional and prospective study of lung function in adults with type 2 diabetes: the atherosclerosis risk in communities (ARIC) study," Diabetes Care, vol. 31, no. 4, pp. 741–746, 2008.
[8] D. J. Cirillo, Y. Agrawal, and P. A. Cassano, "Lipids and pulmonary function in the third national health and nutrition examination survey," The American Journal of Epidemiology, vol. 155, no. 9, pp. 842–848, 2002.
[9] M. Bottai, F. Pistelli, F. di Pede et al., "Longitudinal changes of body mass index, spirometry and diffusion in a general population," European Respiratory Journal, vol. 20, no. 3, pp. 665–673, 2002.
[10] N. Leone, D. Courbon, F. Thomas et al., "Lung function impairment and metabolic syndrome the critical role of abdominal obesity," American Journal of Respiratory and Critical Care Medicine, vol. 179, no. 6, pp. 509–516, 2009.
[11] W. Y. Lin, C. A. Yao, H. C. Wang, and K. C. Huang, "Impaired lung function is associated with obesity and metabolic syndrome in adults," Obesity, vol. 14, no. 9, pp. 1654–1661, 2006.
[12] B. Naveed, M. D. Weiden, S. Kwon, E. J. Gracely, A. L. Comfort, N. Ferrier et al., "Metabolic syndrome biomarkers predict lung function impairment: a nested case-control study," American Journal of Respiratory and Critical Care Medicine, vol. 185, no. 4, pp. 392–399, 2012.
[13] M. W. Johns, "A new method for measuring daytime sleepiness: the epworth sleepiness scale," Sleep, vol. 14, no. 6, pp. 540–545, 1991.
[14] R. Jones, O. Junghard, J. Dent et al., "Development of the GerDQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care," Alimentary Pharmacology and Therapeutics, vol. 30, no. 10, pp. 1030–1038, 2009.
[15] M. R. Miller, J. Hankinson, V. Brusasco et al., "Standardisation of spirometry," European Respiratory Journal, vol. 26, no. 2, pp. 319–338, 2005.
[16] Y. W. Park, S. Zhu, L. Palaniappan, S. Heshka, M. R. Carnethon, and S. B. Heymsfield, "The metabolic syndrome: prevalence and associated risk factor findings in the US population from the third national health and nutrition examination survey, 1988–1994," Archives of Internal Medicine, vol. 163, no. 4, pp. 427–436, 2003.
[17] D. A. Beuther, S. T. Weiss, and E. R. Sutherland, "Obesity and asthma," American Journal of Respiratory and Critical Care Medicine, vol. 174, no. 2, pp. 112–119, 2006.
[18] S. D. Aaron, K. L. Vandemheen, L. P. Boulet et al., "Overdiagnosis of asthma in obese and nonobese adults," Canadian Medical Association Journal, vol. 179, no. 11, pp. 1121–1131, 2008.
[19] C. Irace, C. Cortese, E. Fiaschi et al., "Components of the metabolic syndrome and carotid atherosclerosis: role of elevated blood pressure," Hypertension, vol. 45, no. 4, pp. 597–601, 2005.
[20] D. J. Kim, J. H. Noh, B. W. Lee et al., "The associations of total and differential white blood cell counts with obesity, hypertension, dyslipidemia and glucose intolerance in a Korean population," Journal of Korean Medical Science, vol. 23, no. 2, pp. 193–198, 2008.
[21] W. S. Shim, H. J. Kim, E. S. Kang et al., "The association of total and differential white blood cell count with metabolic syndrome in type 2 diabetic patients," Diabetes Research and Clinical Practice, vol. 73, no. 3, pp. 284–291, 2006.
[22] D. R. Cottam, P. A. Schaefer, G. W. Shaftan, L. Velcu, and L. D. G. Angus, "Effect of surgically-induced weight loss on leukocyte indicators of chronic inflammation in morbid obesity," Obesity Surgery, vol. 12, no. 3, pp. 335–342, 2002.
[23] M. Visser, L. M. Bouter, G. M. McQuillan, M. H. Wener, and T. B. Harris, "Elevated C-reactive protein levels in overweight and obese adults," Journal of the American Medical Association, vol. 282, no. 22, pp. 2131–2135, 1999.
[24] T. Ronti, G. Lupattelli, and E. Mannarino, "The endocrine function of adipose tissue: an update," Clinical Endocrinology, vol. 64, no. 4, pp. 355–365, 2006.
[25] R. V. Considine, M. K. Sinha, M. L. Heiman et al., “Serum immunoreactive-leptin concentrations in normal-weight and obese humans,” The New England Journal of Medicine, vol. 334, no. 5, pp. 292–295, 1996.
[26] H. Kato, S. Ueki, R. Kamada et al., “Leptin has a priming effect on eotaxin-induced human eosinophil chemotaxis,” International Archives of Allergy and Immunology, vol. 155, no. 4, pp. 335–344, 2011.
[27] S. Conus, A. Bruno, and H. U. Simon, “Leptin is an eosinophil survival factor,” The Journal of Allergy and Clinical Immunology, vol. 116, no. 6, pp. 1228–1234, 2005.
[28] D. D. Sin and S. F. P. Man, “Impaired lung function and serum leptin in men and women with normal body weight: a population based study,” Thorax, vol. 58, no. 8, pp. 695–698, 2003.
[29] A. R. Vasudevan, H. Wu, A. M. Xydakis et al., “Eotaxin and obesity,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 1, pp. 256–261, 2006.
[30] H. J. Kim, C. H. Kim, D. H. Lee et al., “Expression of eotaxin in 3T3-L1 adipocytes and the effects of weight loss in high-fat diet induced obese mice,” Nutrition Research and Practice, vol. 5, no. 1, pp. 11–19, 2011.
[31] S. Engeli, M. Feldpausch, K. Gorzelniak et al., “Association between adiponectin and mediators of inflammation in obese women,” Diabetes, vol. 52, no. 4, pp. 942–947, 2003.
[32] F. M. Finucane, J. Luan, N. J. Wareham et al., “Correlation of the leptin: adiponectin ratio with measures of insulin resistance in non-diabetic individuals,” Diabetologia, vol. 52, no. 11, pp. 2345–2349, 2009.
[33] J. H. Yoon, J. K. Park, S. S. Oh, K. H. Lee, S. K. Kim, I. J. Cho et al., “The ratio of serum leptin to adiponectin provides adjunctive information to the risk of metabolic syndrome beyond the homeostasis model assessment insulin resistance: the Korean genomic rural cohort study,” Clinica Chimica Acta, vol. 412, no. 23–24, pp. 2199–2205, 2011.
[34] E. J. Lee, K. H. In, E. S. Ha et al., “Asthma-like symptoms are increased in the metabolic syndrome,” Journal of Asthma, vol. 46, no. 4, pp. 339–342, 2009.
[35] B. H. Thuesen, L. L. N. Husemøen, L. G. Hersoug, C. Pisinger, and A. Linneberg, “Insulin resistance as a predictor of incident asthma-like symptoms in adults,” Clinical and Experimental Allergy, vol. 39, no. 5, pp. 700–707, 2009.
[36] K. M. de Winter-de Groot, C. K. van der Ent, I. Prins, J. M. Tersmette, and C. S. P. M. Uiterwaal, “Exhaled nitric oxide: the missing link between asthma and obesity?” The The Journal of Allergy and Clinical Immunology, vol. 115, no. 2, pp. 419–420, 2005.
[37] T. J. T. Sutherland, J. O. Cowan, S. Young et al., “The association between obesity and asthma: interactions between systemic and airway inflammation,” American Journal of Respiratory and Critical Care Medicine, vol. 178, no. 5, pp. 469–475, 2008.